AstraZeneca Reports Phase 3 extension Data for Tirzepatide in Severe uncontrolled asthma

AstraZeneca today announced Phase 3 extension results for Tirzepatide in patients with Severe uncontrolled asthma. The study demonstrated that Tirzepatide reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Severe uncontrolled asthma and support the continued development of Tirzepatide in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tirzepatide was consistent with previous observations, with no new safety signals identified.